Phase 2 Study of Oral Quisinostat Treatment to Prevent Spread in High-Risk Uveal Melanoma

What this Trial Is About

Researchers are evaluating the effects of quisinostat in preventing the spread of uveal melanoma tumors in patients at high risk. This phase 2 trial focuses on participants diagnosed with high-risk uveal melanoma who have completed primary treatment and have no evidence of metastatic disease. The aim is to understand how quisinostat impacts tumor progression and overall survival in this population. Participants will receive quisinostat orally at a dose of 12 mg three times per week during 21-day cycles, for up to 17 cycles, totaling about 51 weeks of treatment. After completing the treatment phase, participants will be followed for up to 2 years to monitor disease progression. The total duration of participation in the study is approximately three years. Throughout the study, participants will undergo regular assessments to monitor the effects of quisinostat, including distant metastasis-free survival rates, progression-free survival, overall survival, and the identification of tumor recurrence sites. Safety will be monitored by tracking treatment-related adverse events and serious adverse events. Participants must be able to swallow oral medication and meet specific health criteria to join the trial.

Adjuvant Quisinostat in High-Risk Uveal Melanoma